MeSH D006069 - gonorrhea
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Erythromycin | C-solve |  | 1993-07-30 |  |  |
| Ceftriaxone | Ceftriaxone |  | 2007-03-15 |  |  | |
| Ciprofloxacin | Ciprofloxacin |  | 2004-06-09 |  |  | |
| Erythromycin | Erythromycin |  | 2021-02-11 |  |  | |
| Erythromycin lactobionate | Erythromycin Lactobionate |  | 1993-07-30 |  |  | |
| Moxifloxacin | Moxifloxacin |  | 2014-02-18 |  |  | |
| Padagis | Erythromycin | Erythromycin |  | 1983-09-26 |  |  |
| Taro Pharmaceutical | Erythromycin | A/t/s |  | 1982-11-18 |  |  |
| Ciprofloxacin | Ciprofloxacin |  | 2004-10-06 |  |  | |
| Mylan | Erythromycin | E-glades |  | 2002-03-18 |  |  |
| Erythromycin | Erygel |  | 1987-10-21 |  |  | |
| Erythromycin | Erythromycin |  | 1996-07-03 |  |  | |
| Moxifloxacin | Moxifloxacin |  | 2017-05-05 |  |  | |
| NATCO Pharma | Ciprofloxacin | Ciprofloxacin |  | 2004-06-09 |  |  |
| Moxifloxacin | Moxifloxacin |  | 2015-08-31 |  |  | |
| Johnson & Johnson | Erythromycin | Erycette |  | 1985-02-15 |  |  |
| Roche | Ceftriaxone, Lidocaine | Rocephin |  | 1985-03-12 | $261.442 M | Y2021 |
| Lupin Research | Ceftriaxone | Ceftriaxone |  | 2003-09-30 |  |  |
| Moxifloxacin | Moxifloxacin |  | 2014-09-04 |  |  | |
| Cefixime | Suprax |  | 2004-02-23 |  |  |
1
2
3
4
5
6
...
14
>
Clinical Trials
Historical Success Rate
Phase 1
80%4/5
Phase 2
70%7/10
Phase 3
79%33/42
Approved: 29Overall Success rate: 44%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
9
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use